Alexei L Polishchuk1, Richard Li2, Christine Hill-Kayser3, Anthony Little4, Randall A Hawkins5, Jeffrey Hamilton1, Michael Lau1, Hung Chi Tran6, Caron Strahlendorf7, Richard S Lemons8, Vivian Weinberg1, Katherine K Matthay9, Steven G DuBois9, Karen J Marcus2, Rochelle Bagatell4, Daphne A Haas-Kogan10. 1. Department of Radiation Oncology, University of California at San Francisco School of Medicine and UCSF Benioff Children's Hospital, San Francisco, California. 2. Division of Radiation Oncology, Dana Farber/Boston Children's Cancer and Blood Disorders Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 4. Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 5. Department of Radiology, University of California at San Francisco School of Medicine and UCSF Benioff Children's Hospital, San Francisco, California. 6. Division of Hematology/Oncology, Children's Hospital of Los Angeles, Los Angeles, California. 7. Division of Hematology and Oncology, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada. 8. Division of Pediatric Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, Utah. 9. Department of Pediatrics, University of California at San Francisco School of Medicine and UCSF Benioff Children's Hospital, San Francisco, California. 10. Department of Radiation Oncology, University of California at San Francisco School of Medicine and UCSF Benioff Children's Hospital, San Francisco, California. Electronic address: dhaaskogan@radonc.ucsf.edu.
Abstract
PURPOSE/ OBJECTIVES: Despite recent improvements in outcomes, 40% of children with high-risk neuroblastoma will experience relapse, facing a guarded prognosis for long-term cure. Whether recurrences are at new sites or sites of original disease may guide decision making during initial therapy. METHODS AND MATERIALS: Eligible patients were retrospectively identified from institutional databases at first metastatic relapse of high-risk neuroblastoma. Included patients had disease involving metaiodobenzylguanidine (MIBG)-avid metastatic sites at diagnosis and first relapse, achieved a complete or partial response with no more than one residual MIBG-avid site before first relapse, and received no total body irradiation or therapy with (131)I-MIBG before first relapse. Anatomically defined metastatic sites were tracked from diagnosis through first relapse to determine tendency of disease to recur at previously involved versus uninvolved sites and to assess whether this pattern was influenced by site irradiation. RESULTS: Of 159 MIBG-avid metastatic sites identified among 43 patients at first relapse, 131 (82.4%) overlapped anatomically with the set of 525 sites present at diagnosis. This distribution was similar for bone sites, but patterns of relapse were more varied for the smaller subset of soft tissue metastases. Among all metastatic sites at diagnosis in our subsequently relapsed patient cohort, only 3 of 19 irradiated sites (15.8%) recurred as compared with 128 of 506 (25.3%) unirradiated sites. CONCLUSIONS: Metastatic bone relapse in neuroblastoma usually occurs at anatomic sites of previous disease. Metastatic sites identified at diagnosis that did not receive radiation during frontline therapy appeared to have a higher risk of involvement at first relapse relative to previously irradiated metastatic sites. These observations support the current paradigm of irradiating metastases that persist after induction chemotherapy in high-risk patients. Furthermore, they raise the hypothesis that metastatic sites appearing to clear with induction chemotherapy may also benefit from radiotherapeutic treatment modalities (external beam radiation or (131)I-MIBG).
PURPOSE/ OBJECTIVES: Despite recent improvements in outcomes, 40% of children with high-risk neuroblastoma will experience relapse, facing a guarded prognosis for long-term cure. Whether recurrences are at new sites or sites of original disease may guide decision making during initial therapy. METHODS AND MATERIALS: Eligible patients were retrospectively identified from institutional databases at first metastatic relapse of high-risk neuroblastoma. Included patients had disease involving metaiodobenzylguanidine (MIBG)-avid metastatic sites at diagnosis and first relapse, achieved a complete or partial response with no more than one residual MIBG-avid site before first relapse, and received no total body irradiation or therapy with (131)I-MIBG before first relapse. Anatomically defined metastatic sites were tracked from diagnosis through first relapse to determine tendency of disease to recur at previously involved versus uninvolved sites and to assess whether this pattern was influenced by site irradiation. RESULTS: Of 159 MIBG-avid metastatic sites identified among 43 patients at first relapse, 131 (82.4%) overlapped anatomically with the set of 525 sites present at diagnosis. This distribution was similar for bone sites, but patterns of relapse were more varied for the smaller subset of soft tissue metastases. Among all metastatic sites at diagnosis in our subsequently relapsed patient cohort, only 3 of 19 irradiated sites (15.8%) recurred as compared with 128 of 506 (25.3%) unirradiated sites. CONCLUSIONS: Metastatic bone relapse in neuroblastoma usually occurs at anatomic sites of previous disease. Metastatic sites identified at diagnosis that did not receive radiation during frontline therapy appeared to have a higher risk of involvement at first relapse relative to previously irradiated metastatic sites. These observations support the current paradigm of irradiating metastases that persist after induction chemotherapy in high-risk patients. Furthermore, they raise the hypothesis that metastatic sites appearing to clear with induction chemotherapy may also benefit from radiotherapeutic treatment modalities (external beam radiation or (131)I-MIBG).
Authors: Dana L Casey; Ken L Pitter; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-09 Impact factor: 7.038
Authors: Kieuhoa T Vo; Steven G DuBois; John Neuhaus; Steve E Braunstein; Brent R Weil; Arlene Naranjo; Sabine Irtan; Julia Balaguer; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2022-02-21 Impact factor: 3.838
Authors: Alexander F Bagley; David R Grosshans; Nancy V Philip; Jennifer Foster; Mary Frances McAleer; Susan L McGovern; Yasmin Lassen-Ramshad; Anita Mahajan; Arnold C Paulino Journal: Pediatr Blood Cancer Date: 2019-05-02 Impact factor: 3.167
Authors: Jaques van Heerden; Mariana Kruger; Tonya Esterhuizen; Marc Hendricks; Jennifer Geel; Ané Büchner; Gita Naidu; Jan du Plessis; Barry Vanemmenes; Ronelle Uys; G P Hadley Journal: Pediatr Surg Int Date: 2020-02-28 Impact factor: 1.827
Authors: Christine Chung; Tom Boterberg; John Lucas; Joseph Panoff; Dominique Valteau-Couanet; Barbara Hero; Rochelle Bagatell; Christine E Hill-Kayser Journal: Pediatr Blood Cancer Date: 2021-05 Impact factor: 3.167
Authors: Annu Singh; Shakeel Modak; Armand K Solano; Brian H Kushner; Suzanne Wolden; Joseph Huryn; Cherry L Estilo Journal: Pediatr Blood Cancer Date: 2021-01-28 Impact factor: 3.167
Authors: Ji Hwan Jo; Seung Do Ahn; Minji Koh; Jong Hoon Kim; Sang-Wook Lee; Si Yeol Song; Sang Min Yoon; Young Seok Kim; Su Ssan Kim; Jin-Hong Park; Jinhong Jung; Eun Kyung Choi Journal: Radiat Oncol J Date: 2019-09-30